Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to an analyst's considerable price target raise. Sarepta's gain trounced that of the S 500 index, which bumped almost 0.3% higher on the day.

Before market open, JPMorgan Chase prognosticator Anupam Rama reset his price target on Sarepta to $177 per share. That's well above his previous level of $112. Not surprisingly, he maintained his overweight (buy, in other words) recommendation on the veteran biotech company.

In his research note detailing the change, Rama wrote of the opportunity presented by the treatment of Duchenne muscular dystrophy (DMD). Sarepta has won approval for several medications for the disorder and has more currently in development.

Continue reading

Source Fool.com